Tech Company Financing Transactions

PhaseBio Pharmaceuticals Funding Round

AstraZeneca, Fletcher Spaght Ventures and Hatteras Venture Partners participated in a $40 million Series C venture round for PhaseBio Pharmaceuticals. The funding round was announced on 3/12/2015.

Transaction Overview

Company Name
PhaseBio Pharmaceuticals
Announced On
3/12/2015
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series C
Investors

AstraZeneca (Lead Investor) (Michael Gutch)

Fletcher Spaght Ventures (Guy Fish)

Hatteras Venture Partners (Clay Thorp)

Johnson & Johnson Development Corporation

New Enterprise Associates (James Barrett)

Proceeds Purpose
Funding proceeds will enable progression of PhaseBio's once-weekly insulin (PE0139) into Phase 2a testing for type 2 diabetes and once-weekly Vasoactive Intestinal Peptide (PB1046) into separate Phase 2a trials for heart failure and for cardiomyopathy in Duchenne and Becker muscular dystrophy.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1 Great Valley Pkwy. 30
Malvern, PA 19355
USA
Phone
(610) 981-6500
Website
www.phasebio.com
Email Address
Not Recorded
Overview
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), located in Malvern, PA, is a development stage, privately held protein engineering company focused on developing the next generation of biopharmaceuticals.
Profile
PhaseBio Pharmaceuticals LinkedIn Company Profile
Social Media
PhaseBio Pharmaceuticals Company Twitter Account
Company News
PhaseBio Pharmaceuticals News
Facebook
PhaseBio Pharmaceuticals on Facebook
YouTube
PhaseBio Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jonathan Mow
  Jonathan Mow LinkedIn Profile  Jonathan Mow Twitter Account  Jonathan Mow News  Jonathan Mow on Facebook
Chief Financial Officer
John Sharp
  John Sharp LinkedIn Profile  John Sharp Twitter Account  John Sharp News  John Sharp on Facebook
Chief Medical Officer
John Lee
  John Lee LinkedIn Profile  John Lee Twitter Account  John Lee News  John Lee on Facebook
VP - Bus. Development
Susan Arnold
  Susan Arnold LinkedIn Profile  Susan Arnold Twitter Account  Susan Arnold News  Susan Arnold on Facebook
VP - Bus. Development
Michael York
  Michael York LinkedIn Profile  Michael York Twitter Account  Michael York News  Michael York on Facebook
VP - R & D
James Ballance
  James Ballance LinkedIn Profile  James Ballance Twitter Account  James Ballance News  James Ballance on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/12/2015: Tigo Energy venture capital transaction
Next: 3/12/2015: Highfive venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to document tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.